. 2021 Jul 29;5(5):e1507. doi: 10.1002/cnr2.1507

TABLE 5.

Prognostic factors for the prognosis in the patients classified by the hENT1 expression by each antibody

Variables	Univariate		Multivariate
Variables	Hazard ratio (95% Confidence interval)	p	Hazard ratio (95% Confidence interval)	p
The patients with 10D7G2^Low (n = 79)
Residual tumor status (R1/R0)	1.81 (0.96–3.41)	0.067	1.67 (0.88–3.18)	0.116
Adjuvant agent (GEM/S‐1)	2.44 (1.45–4.12)	0.001	2.39 (1.41–4.06)	0.001
The patients with 10D7G2^High (n = 16)
CA19‐9 (>37 U/ml/≤37 U/ml)	4.77 (0.79–28.9)	0.089	4.86 (0.79–29.8)	0.088
Adjuvant agent (GEM/S‐1)	0.94 (0.22–3.94)	0.931	1.17 (0.26–5.37)	0.931
The patients with SP120^Low (n = 295)
Residual tumor status (R1/R0)	2.35 (1.63–3.38)	<0.001	1.88 (1.30–2.74)	0.001
Primary tumor status (T3‐T4/T1‐2)	2.64 (1.50–4.63)	0.001	2.14 (1.19–3.85)	0.011
Regional lymph node status (N1/N0)	1.83 (1.35–2.48)	<0.001	1.50 (1.08–2.07)	0.015
CA19‐9 (>37 U/ml/≤37 U/ml)	1.87 (1.37–2.57)	<0.001	1.59 (1.15–2.20)	0.005
Adjuvant agent (GEM/S‐1)	1.73 (1.31–2.28)	<0.001	1.84 (1.39–2.44)	<0.001
The patients with SP120^High (n = 31)
ECOG performance status (1/0)	2.60 (1.08–6.27)	0.033	2.75 (1.03–7.33)	0.044
CA19‐9 (>37 U/ml/≤37 U/ml)	2.81 (1.19–6.64)	0.018	2.47 (0.50–3.35)	0.047
Adjuvant agent (GEM/S‐1)	0.93 (0.40–2.16)	0.872	0.77 (0.30–2.00)	0.592

Abbreviations: GEM, gemcitabine; hENT1, human equilibrative nucleoside transporter‐1.